MedTrace Logo

IVF Outcome Following Progestogen Ovarian Stimulation

NCT04175990 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2019-11-26

No results posted yet for this study

Summary

The new strategy is by using the progestogen to block the luteinizing hormone(LH) surge either endogenous during luteal phase stimulation, or exogenous in the follicular phase i.e progestin primed ovarian stimulation (PPOS). The goal of PPOS is to develop a single dominant follicle. Various types of oral Progestin had been studied before including Medroxyprogesterone Acetate (MPA) and Utrogestan with different dosage. A different study by Wang et al conducted by using MPA to patients with PCOS. The use of MPA is contraindicated in human pregnancy whereas Dydrogesterone had been extensively used worldwide for the treatment of threatened miscarriage as well as luteal support in infertility setting. Previous protocol on PPOS showed inconclusive results. Therefore in this study, Dydrogesterone was used as the Progestin Primed Ovarian hyperstimulation to explore its effect on PCOS women IVF outcome.

Conditions

  • IVF
  • Oocyte Maturation Defect 1
  • Clinical Pregnancy Rate
  • Ovarian Hyperstimulation

Interventions

DRUG

Dydrogesterone Pill

started from day 1 of menses till trigger day

Sponsors & Collaborators

  • National University of Malaysia

    lead OTHER

Principal Investigators

  • Muhammad azrai abu, medical Degree · Department of Obstetrics and Gynecology, UKM Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-10
Primary Completion
2019-03-10
Completion
2019-05-09

Countries

  • Malaysia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175990 on ClinicalTrials.gov